Work

Brensocatib – an editorial on the new chapter in noncystic fibrosis bronchiectasis treatment

Year: 2025

Type: article

Abstract: Bronchiectasis is a chronic airway disease marked by irreversible bronchial dilation, persistent cough, and recurrent infections. Its pathogenesis is explained by the "vicious cycle hypothesis," which involves impaired mucociliary clearance, neutrophil activation, and tissue damage from neutrophil serine proteinases (NSPs). In August 2025, the FDA approved Brensocati, a selective dipeptidyl peptidase-1 (DPP-1) inhibitor, as the first disease-modifying therapy for bronchiectasis. By blocking NSP activation, Brensocatib reduces inflammation and exacerbation. WILLOW and ASPEN trials demonstrated significant improvements in exacerbation rates, lung function decline, and exacerbation-free survival, establishing a novel therapeutic paradigm for this previously undertreated condition.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000003976

Authors: Muhammad Furqan, Muhammad Usman Haider, Sadia Binte Rahim

Institutions: King Edward Medical University, Geisinger Health System, Mymensingh Medical College Hospital

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850